Article
Multidisciplinary Sciences
Kohei Shitara, Jaffer A. Ajani, Markus Moehler, Marcelo Garrido, Carlos Gallardo, Lin Shen, Kensei Yamaguchi, Lucjan Wyrwicz, Tomasz Skoczylas, Arinilda Campos Bragagnoli, Tianshu Liu, Mustapha Tehfe, Elena Elimova, Ricardo Bruges, Thomas Zander, Sergio de Azevedo, Ruben Kowalyszyn, Roberto Pazo-Cid, Michael Schenker, James M. Cleary, Patricio Yanez, Kynan Feeney, Michalis Karamouzis, Valerie Poulart, Ming Lei, Hong Xiao, Kaoru Kondo, Mingshun Li, Yelena Y. Janjigian
Summary: In patients with gastro-oesophageal adenocarcinoma, nivolumab plus chemotherapy has shown superior overall survival compared to chemotherapy alone.
Article
Oncology
Karen L. Reckamp, Mary W. Redman, Konstantin H. Dragnev, Katherine Minichiello, Liza C. Villaruz, Bryan Faller, Tareq Al Baghdadi, Susan Hines, Leah Everhart, Louise Highleyman, Vassiliki Papadimitrakopoulou, David R. Gandara, Karen Kelly, Roy S. Herbst
Summary: This randomized phase II trial demonstrated that the combination of ramucirumab and pembrolizumab significantly improved overall survival in patients with advanced non-small-cell lung cancer previously treated with immune checkpoint inhibitors and chemotherapy. The safety profile of this combination therapy was consistent with the known toxicities of both drugs.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Peter H. O'Donnell, Matthew I. Milowsky, Daniel P. Petrylak, Christopher J. Hoimes, Thomas W. Flaig, Nataliya Mar, Helen H. Moon, Terence W. Friedlander, Rana R. McKay, Mehmet A. Bilen, Sandy Srinivas, Earle F. Burgess, Chethan Ramamurthy, Saby George, Daniel M. Geynisman, Sergio Bracarda, Delphine Borchiellini, Lionnel Geoffrois, Jose Pablo Maroto Rey, Christiano Ferrario, Anne-Sophie Carret, Yao Yu, Maria Guseva, Blanca Homet Moreno, Jonathan E. Rosenberg
Summary: EV + Pembro demonstrated a high confirmed objective response rate (cORR) with durable responses as a first-line treatment in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer (la/mUC). Patients who received EV monotherapy had a response and safety profile consistent with previous studies. Adverse events for EV + Pembro were manageable, with no new safety signals observed.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
Michiel S. van der Heijden, Thomas Powles, Daniel Petrylak, Ronald de Wit, Andrea Necchi, Cora N. Sternberg, Nobuaki Matsubara, Hiroyuki Nishiyama, Daniel Castellano, Syed A. Hussain, Aristotelis Bamias, Georgios Gakis, Jae-Lyun Lee, Scott T. Tagawa, Ulka Vaishampayan, Jeanny B. Aragon-Ching, Bernie J. Eigl, Rebecca R. Hozak, Erik R. Rasmussen, Meng Summer Xia, Ryan Rhodes, Sameera Wijayawardana, Katherine M. Bell-McGuinn, Amit Aggarwal, Alexandra Drakaki
Summary: This study identifies potential predictive biomarkers for survival benefit in patients with platinum-refractory advanced urothelial carcinoma treated with the anti-VEGFR2 monoclonal antibody ramucirumab. Higher PD-L1 IHC and immune pathway scores are associated with greater ramucirumab overall survival (OS) benefit. Basal molecular subtypes show greater OS benefit compared to Luminal subtypes. Patients from East Asia have lower immune/angiogenesis signature scores, correlating with decreased ramucirumab OS benefit. The study highlights the importance of multiple biomarkers in identifying patients who might benefit the most from treatment with ramucirumab.
NATURE COMMUNICATIONS
(2022)
Article
Multidisciplinary Sciences
Sun Min Lim, Solange Peters, Ana Laura Ortega Granados, Gustavo dix Junqueira Pinto, Christian Sebastian Fuentes, Giuseppe Lo Russo, Michael Schenker, Jin Seok Ahn, Martin Reck, Zsolt Szijgyarto, Neda Huseinovic, Eleftherios Zografos, Elena Buss, Neda Stjepanovic, Sean ODonnell, Filippo de Marinis
Summary: This study compared the efficacy and safety of two different anti-PD-1 antibodies, dostarlimab and pembrolizumab, combined with chemotherapy as first-line treatment in patients with metastatic NSCLC. The results showed similar efficacy between the two antibodies, with dostarlimab performing better in the PD-L1-positive subgroup. Additionally, the DCT treatment group had a longer progression-free survival, but there was no significant difference in overall survival between the two groups.
NATURE COMMUNICATIONS
(2023)
Review
Medicine, General & Internal
Sarya Swed, Nour Shaheen, Wael Hafez, Nesreen Elsayed Talat, Samah S. S. Rozan, Rehab Diab, Abdulqadir J. J. Nashwan, Karam R. R. Motawea, Hidar Alibrahim, Mhd Kutaiba Albuni, Elias Battikh, Bisher Sawaf, Sheikh Shoib
Summary: This study compared the effectiveness and safety of pembrolizumab and paclitaxel as a second line treatment for locally advanced gastroesophageal cancer. The results showed no significant difference in objective response rate between the two drugs, indicating that doctors can consider either treatment option based on patient conditions.
Review
Gastroenterology & Hepatology
Leonardo Henry Eusebi, Giovanna Grazia Cirota, Rocco Maurizio Zagari, Alexander Charles Ford
Summary: Chronic gastro-oesophageal reflux can lead to the development of Barrett's oesophagus or oesophageal adenocarcinoma. Global prevalence of Barrett's oesophagus varies geographically and is significantly higher in men. Low-grade dysplasia is common in histologically confirmed cases of Barrett's oesophagus.
Article
Oncology
Mike Wenzel, Marina Deuker, Luigi Nocera, Claudia Colla Ruvolo, Zhe Tian, Shahrokh F. Shariat, Fred Saad, Alberto Briganti, Andreas Becker, Luis A. Kluth, Felix K. H. Chun, Pierre Karakiewicz
Summary: Variant histology in urethral cancer is associated with higher cancer specific mortality compared to urothelial histology. Chemotherapy improves survival in metastatic urethral cancer patients with adenocarcinoma and other variant histology, but not in those with squamous cell carcinoma.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Sunyoung Lee, Rachna T. Shroff, Shalini Makawita, Lianchun Xiao, Anaemy Danner De Armas, Priya Bhosale, Kavitha Reddy, Ahmed Shalaby, Kanwal Raghav, Shubham Pant, Robert A. Wolff, Milind Javle
Summary: This study demonstrates that the monoclonal antibody ramucirumab targeting VEGFR-2 has a certain efficacy in the treatment of advanced biliary tract cancers, with good tolerability similar to other chemotherapy regimens historically used for chemorefractory BTC.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Brett H. Herzog, Saiama N. Waqar, Siddhartha Devarakonda, Jeffrey P. Ward, Feng Gao, Ramaswamy Govindan, Daniel Morgensztern
Summary: This single institution phase II study investigated the combination of ramucirumab and atezolizumab in heavily pretreated patients with advanced NSCLC. Although the primary endpoint of overall response rate was not met, the treatment showed a high clinical benefit rate and overall survival better than expected. Further research on the combination of immune checkpoint inhibitors and VEGF inhibition is warranted.
Article
Pharmacology & Pharmacy
Meiyu Wu, Shuxia Qin, Liting Wang, Chongqing Tan, Ye Peng, Xiaohui Zeng, Xia Luo, Lidan Yi, Xiaomin Wan
Summary: This study evaluated the cost-effectiveness of pembrolizumab plus chemotherapy as first-line therapy for advanced oesophageal cancer from the perspective of the Chinese healthcare system. The results showed that this treatment approach was not cost-effective compared to placebo plus chemotherapy.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Multidisciplinary Sciences
Karin Wallander, Jesper Eisfeldt, Mats Lindblad, Daniel Nilsson, Kenny Billiau, Hassan Foroughi, Magnus Nordenskjold, Agne Lieden, Emma Tham
Summary: The study demonstrated that low-coverage whole-genome sequencing could serve as an effective tool for analyzing cell-free tumor DNA and total CNAs in plasma from patients with gastro-esophageal cancer. Additionally, some patients showed corresponding CNAs in plasma as seen in tumor tissue, indicating the potential clinical relevance of this liquid biopsy approach.
Article
Gastroenterology & Hepatology
Aurelien Marabelle, Philippe A. Cassier, Marwan Fakih, Steven Kao, Dorte Nielsen, Antoine Italiano, Tormod Kyrre Guren, Marloes G. J. van Dongen, Kristen Spencer, Giovanni Mendonca Bariani, Paolo A. Ascierto, Armando Santoro, Manisha Shah, Jamil Asselah, Syma Iqbal, Shunji Takahashi, Sarina A. Piha-Paul, Patrick A. Ott, Arkendu Chatterjee, Fan Jin, Kevin Norwood, Jean-Pierre Delord
Summary: The study evaluated the efficacy and safety of Pembrolizumab in patients with advanced anal squamous cell carcinoma, showing that it may be a favorable treatment option for this disease. Efficacy analysis showed an objective response in 11% of patients, while safety analysis revealed treatment-related adverse events in 61% of patients.
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2022)
Review
Oncology
Mary E. Booth, Elizabeth C. Smyth
Summary: Initial studies have shown limited improvement in survival for immune checkpoint inhibitors in unselected gastro-oesophageal cancer. However, recent clinical trials suggest that immunotherapies may offer significant clinical benefit in certain populations. The heterogeneity of gastro-oesophageal cancer in terms of histopathological and molecular features makes it important to identify the populations most likely to benefit from immune checkpoint inhibitors. Programmed death-ligand 1 expression is an important biomarker, but its threshold for determining benefits varies across trials. Patients with certain characteristics, such as microsatellite instability, high tumour mutational burden, and Epstein-Barr Virus positivity, are more likely to benefit from immunotherapy even in programmed death-ligand 1-negative populations.
Article
Medicine, General & Internal
Dag Holmberg, Giola Santoni, My von Euler-Chelpin, Martti Farkkila, Joonas H. Kauppila, John Maret-Ouda, Eivind Ness-Jensen, Jesper Lagergren
Summary: Patients with non-erosive gastro-oesophageal reflux disease have a similar incidence of oesophageal adenocarcinoma as the general population.
BMJ-BRITISH MEDICAL JOURNAL
(2023)
Article
Pharmacology & Pharmacy
Irene Y. Chong, Ian Chau
Summary: Stomach cancer is a global health problem that requires multimodality treatment for locally advanced cases. The use of chemoradiotherapy after D2 gastrectomy has not been supported by the best evidence so far. Ongoing trials with translational endpoints will provide important guidance for the use of chemoradiotherapy in the neoadjuvant setting. Radiotherapy can effectively alleviate symptoms of advanced gastric cancer and Stereotactic Body Radiotherapy shows promise in controlling oligometastatic liver disease in some patients.
CURRENT OPINION IN PHARMACOLOGY
(2023)
Article
Oncology
Victor Moreno, Ruth Perets, Tamar Peretz-Yablonski, Nele Fourneau, Suzette Girgis, Yue Guo, Peter Hellemans, Raluca Verona, Natalia Pendas, Qi Xia, Ravit Geva, Emiliano Calvo
Summary: Mitazalimab, a human monoclonal antibody targeting CD40, was evaluated in this study for anti-tumor immunotherapy. The results demonstrated its manageable safety profile and pharmacokinetic/pharmacodynamic properties, suggesting its potential as a treatment option for solid malignancies.
INVESTIGATIONAL NEW DRUGS
(2023)
Article
Oncology
David K. Lau, Maria Aresu, Timothy Planche, Amina Tran, Retchel Lazaro-Alcausi, Julie Duncan, Shannon Kidd, Susan Cromarty, Ruwaida Begum, Isma Rana, Su Li, Ali Abdulnabi Mohamed, Irene Monahan, David J. Clark, Nicholas Eckersley, Henry M. Staines, Elisabetta Groppelli, Sanjeev Krishna, Martin Mayora-Neto, Nigel Temperton, Charlotte Fribbens, David Watkins, Naureen Starling, Ian Chau, David Cunningham, Sheela Rao
Summary: The study evaluated the prevalence of neutralizing antibodies in 152 gastrointestinal cancer patients receiving chemotherapy after SARS-CoV-2 vaccination, finding that despite the immunosuppressive effects of chemotherapy, two doses of vaccines can still induce a protective immune response in patients undergoing treatment.
Article
Oncology
Eric Van Cutsem, Maria di Bartolomeo, Elizabeth Smyth, Ian Chau, Haeseong Park, Salvatore Siena, Sara Lonardi, Zev A. Wainberg, Jaffer Ajani, Joseph Chao, Yelena Janjigian, Amy Qin, Jasmeet Singh, Ferdous Barlaskar, Yoshinori Kawaguchi, Geoffrey Ku
Summary: The DESTINY-Gastric02 trial is a phase 2 study evaluating the efficacy of trastuzumab deruxtecan in HER2-positive advanced gastric and gastro-oesophageal junction cancer. The results demonstrate clinically meaningful response rates, supporting its use as second-line therapy for these patients.
Article
Cell Biology
Ignacio Melero, Tamara Tanos, Mariana Bustamante, Miguel F. Sanmamed, Emiliano Calvo, Irene Moreno, Victor Moreno, Tatiana Hernandez, Maria Martinez Garcia, Alejo Rodriguez-Vida, Josep Tabernero, Analia Azaro, Mariano Ponz-Sarvise, Iben Spanggaard, Kristoffer Rohrberg, Ernesto Guarin, Eveline Nuesch, Iakov I. Davydov, Chiahuey Ooi, Jose Duarte, Evelyne Chesne, Christine McIntyre, Maurizio Ceppi, Marta Canamero, Oliver Krieter
Summary: This first-in-human study evaluated the effectiveness of RO7122290, a bispecific fusion protein, in stimulating T cells for improved tumor cell killing in FAP-expressing tumors. The study involved administering escalating doses of RO7122290, both as a single agent and in combination with atezolizumab, to patients with advanced or metastatic solid tumors. The results showed promising pharmacokinetics and treatment-induced changes in peripheral and tissue biomarkers, supporting further evaluation of RO7122290 in combination with immune-oncology agents for solid tumor treatment.
SCIENCE TRANSLATIONAL MEDICINE
(2023)
Letter
Oncology
Dima El-Sharkawi, Amit Sud, Catherine Prodger, Jahanzaib Khwaja, Rohan Shotton, Brian Hanley, Victoria Peacock, Ying Ying Peng, Anita Arasaretnam, Sarkhara Sharma, Frances Aldridge, Bhupinder Sharma, Andrew Wotherspoon, Betty Cheung, Corinne De Lord, Rosalynd Johnston, Shireen Kassam, Ruth Pettengel, Kim Linton, Paul Greaves, Lucy Cook, Kikkeri N. Naresh, Kate Cwynarski, Toby A. Eyre, Ian Chau, David Cunningham, Sunil Iyengar
BLOOD CANCER JOURNAL
(2023)
Article
Oncology
Lucia Paniagua-Herranz, Bernard Doger, Cristina Diaz-Tejeiro, Adrian Sanvicente, Cristina Nieto-Jimenez, Victor Moreno, Pedro Perez Segura, Balazs Gyorffy, Emiliano Calvo, Alberto Ocana
Summary: This study explored the high expression of EGFR and MET in prostate adenocarcinoma and pancreatic adenocarcinoma, and found that it was related to high expression of PD-L1, suggesting the potential for future combination therapy using bi-specific EGFR/MET antibodies and anti-PD(L)1 inhibitors.
Article
Oncology
Funda Meric-Bernstam, Emiliano Calvo, Keun Seok Lee, Victor Moreno, Yeon Hee Park, Sun Young Rha, Pavani Chalasani, Wei Zhong, Li Zhou, Steven Pirie-Shepherd, Abraham C. F. Leung, Giuseppe Curigliano
Summary: This study evaluated the safety and antitumor activity of PF-06804103 in patients with advanced/unresectable or metastatic breast and gastric cancers. The results showed that PF-06804103 demonstrated antitumor activity, but adverse events led to a high rate of treatment discontinuation.
MOLECULAR CANCER THERAPEUTICS
(2023)
Review
Immunology
Atanasio Pandiella, Emiliano Calvo, Victor Moreno, Eitan Amir, Arnoud Templeton, Alberto Ocana
Summary: This review discusses the successful application of immune system targeting in cancer treatment and explores the relevant concepts and strategies that should be considered during clinical development. In addition, solutions to overcome the limitations of approved and investigational drugs are provided.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Hazel Lote, Florentia Mousoullou, George Vlachogiannis, Andrea Lampis, Laura Satchwell, Clare Peckitt, Caroline Fong, Ruwaida Begum, Shannon Kidd, Susan Cromarty, Anderley Gordon, Charlotte Fribbens, Sheela Rao, Naureen Starling, Ian Chau, David Cunningham, Nicola Valeri
Summary: This study identified miR-148a-3p as a potential biomarker for trastuzumab-based therapy in HER2-positive oesophago-gastric cancer patients. The results showed that the expression level of miR-148a-3p is associated with patient survival and progression rates.
FRONTIERS IN ONCOLOGY
(2023)
Meeting Abstract
Biophysics
Shima Ismail, Farheen Mir, Chloe Anthias, Sandra Easdale, Mike Potter, Mark Ethell, Carlos Arias, Bhupinder Sharma, David Cunningham, Ian Chau, Sunil Iyengar, Dima El-Sharkawi, Emma Nicholson
BONE MARROW TRANSPLANTATION
(2023)
Meeting Abstract
Oncology
Hazel Lote, Florentia Mousoullou, George Vlachogiannis, Caroline Fong, Laura Satchwell, Clare Peckitt, Ruwaida Begum, Shannon Kidd, Susan Cromarty, Anderley Gordon, Charlotte Victoria Fribbens, David J. Watkins, Sheela Rao, Ian Chau, Naureen Starling, David Cunningham, Nicola Valeri
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Meeting Abstract
Oncology
Mairead Geraldine McNamara, Jayne Swain, Zoe Craig, Rohini Sharma, Olusola Olusesan Faluyi, Jonathan Wadsley, Carys Morgan, Lucy R. Wall, Ian Chau, Nick Reed, Debashis Sarker, Jane Margetts, Daniel Krell, Judith Cave, Sothi Sharmila, Alan Anthoney, Alkesh Patel, Angela Lamarca, Richard Hubner, Juan W. Valle
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Meeting Abstract
Oncology
Susanna Slater, Annette Bryant, Maria Aresu, Ruwaida Begum, Hsiang-Chi Chen, Clare Peckitt, Retchel Lazaro-Alcausi, Paul Carter, Gayathri Anandappa, Shelize Khakoo, Graham Branagan, Nicol George, Muti Abulafi, Sarah Duff, Nicholas West, Leslie Bucheit, Thereasa A. Rich, Ian Chau, Naureen Starling, David Cunningham
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Meeting Abstract
Oncology
Avani Athauda, Tatiany Silveira, Thomas Lund, Katharina von Loga, Benjamin Challoner, Isma Rana, Janet Thomas, Naureen Starling, Ian Chau, Sheela Rao, David J. Watkins, David Cunningham, Marco Gerlinger
JOURNAL OF CLINICAL ONCOLOGY
(2023)